Key result
Addition of sirolimus to aggressive immunosuppressive therapy resulted in the patient remaining disease-free from recurrent giant cell myocarditis post-heart transplantation.
Why the study?
Does sirolimus prevent recurrence of giant cell myocarditis in a heart transplant recipient?
Population
1 patient with recurrent giant cell myocarditis after orthotopic heart transplantation and a history of…
Design
Case_report
Authors
Loading...
May inform individualized therapy for recurrent post-transplant GCM with Crohn disease; hypothesis-generating and should not yet change practice.
Case Report (n=1)
Does sirolimus prevent recurrence of giant cell myocarditis in a heart transplant recipient?
Sirolimus may be an effective adjunctive therapy for preventing recurrence of giant cell myocarditis after heart transplantation.
Patel et al. (2018) conducted a case report in Recurrent Giant Cell Myocarditis (n=1). Sirolimus was evaluated on Disease recurrence. Addition of sirolimus to aggressive immunosuppressive therapy resulted in the patient remaining disease-free from recurrent giant cell myocarditis post-heart transplantation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: